Targeted agents like dasatinib for BCR::ABL1 ALL, selumetinib for BRAF mutant gliomas, and PARP inhibitors for cancers with loss of homologous repair showed activity in relevant pediatric preclinical models. This evidence concerns the gene BCR and central nervous system cancer.